Ajanta Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Ajanta Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ajanta Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ajanta Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Ajanta Pharma Ltd (Ajanta Pharma) is a specialty pharmaceutical company. The company is engaged in the development, manufacturing, and marketing of branded generics and generic pharmaceutical products across various therapies such as Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, Gynaecology, Anti-Diabetes, Antibiotic, Anti-Malarial, Respiratory, Paediatric, and General Health. Its products are offered to patients through a network of CFAs, sales teams, distribution partners, and stockists in Africa, Asia, and North America. Ajanta operates manufacturing unit in Gujarat, Maharashtra, Assam, and Madhya Pradesh. The company also supplies multivitamins, eye drops, cough syrups, and antibiotics to government bodies in India. Ajanta Pharma is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Ajanta House, Charkop, Kandivli West, Mumbai, Maharashtra, 400067
Website
www.ajantapharma.com
Telephone
91 226 60609000
No of Employees
11,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AJANTPHARM (NSE)
Revenue (2025)
$625.8M
17.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
14.7%
(2025 vs 2024)
Market Cap*
$4.5B
Net Profit Margin (2025)
XYZ
-2.2%
(2025 vs 2024)
* As of and is in US$
Ajanta Pharma Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Branded | Valif |
| Generic Medicines: | Artefan |
| Diabetes | Met XL |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In August, the company received approval from the US FDA for topiramate extended-release capsules. |
| 2018 | Corporate Awards | In July, Mr. Yogesh Agrawal, the Managing Director and Mr. Rajesh Agrawal, the Joint Managing Director were awarded the “best CEO of the year – Next Gen” award by CNBC-Awaaz. |
| 2017 | Regulatory Approval | in November, the company received approval from the US FDA to launch Clonidine Hydrochloride Extended Release Tablets in the US. |
Competitor Comparison
| Key Parameters | Ajanta Pharma Ltd | Aurobindo Pharma Ltd | Alembic Pharmaceuticals Ltd | Kopran Ltd | Syncom Formulations (India) Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Hyderabad | Vadodara | Mumbai | Indore |
| State/Province | Maharashtra | Telangana | Gujarat | Maharashtra | Madhya Pradesh |
| No. of Employees | 11,000 | 9,107 | 16,571 | 800 | 554 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mannalal B. Agrawal | Chairman | Executive Board | 1979 | 79 |
| Rajesh Mannalal Agrawal | Director; Joint Managing Director | Executive Board | 2013 | - |
| Yogesh Mannalal Agrawal | Director; Managing Director | Executive Board | 2000 | - |
| Arvind K. Agrawal | Chief Financial Officer | Senior Management | - | - |
| Madhusudan B. Agrawal | Director; Vice Chairman | Executive Board | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer